Home THIS WEBSITE IS INTENDED FOR HEALTHCARE PROFESSIONALS (HCPs) ONLY

WELCOME to the SYLVANT®  Healthcare Professional site

Diagnosis
Treament
Efficacy
Tolerability
Mode of Action
Dosing & Administration
Clinical Papers

Diagnosis of iMCD

Diagnosis of iMCD

02:32

Dr. James Cavet
Consultant Haematologist, UK
In this video, Dr James Cavet discusses the symptoms of iMCD and the diagnostic pathway needed to make a correct diagnosis.

Treatment of iMCD

Treatment of iMCD

01:52

Dr. James Cavet
Consultant Haematologist, UK
In this video, Dr James Cavet discusses the treatment of iMCD using SYLVANT®.

Long term management of iMCD

Long term management of iMCD

01:58

Dr. James Cavet
Consultant Haematologist, UK
In this video, Dr James Cavet discusses long-term maintenance to reduce the risk of iMCD flares.

THE JOURNEY BEGINS HERE

From initial diagnosis to managing adverse events, this site has the guidance and information needed for every step of the way.

Click the link to view supporting information.

View All Resources

 

iMCD IS NOT AN INDOLENT DISEASE

iMCD is a very heterogenous disease and there is no typical patient. Uncontrolled iMCD can lead to severe organ damage, increased risk of developing cancers and death3

The median age of diagnosis is 50 One-third of patients die within five years of diagnosis iMCD is a disease, with approximately 540-960 diagnoses a year in the USA iMCD is a disease, affecting all populations; with diagnosis in an age range of 2-80 years

References

  1. van Rhee F, Voohees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018; 132 (20): 2115-2125
  2. Abramson JS. Diagnosis and management of Castleman disease. J Natl Compr Canc Netw. 2019; 17(11.5): 1417-1419.
  3. Liu AY et al. The Lancet Haematology 2016.
  4. Fajgenbaum DC et al. Blood 2017; 129(12): 1646-1657.

EUSA Sylvant © 2021 EUSA Pharma      Date of prep: November 2021    GL-SIL-2100100

This medicinal product is subject to additional monitoring.
Adverse events to medicinal products should be reported.
Reporting forms and information can be found at your local health authority website.
To report a potential adverse event with an EUSA product please send an email to safety@eusapharma.com.
This website is developed and funded by EUSA for healthcare professionals only.
This website will not collect any personal or private information.

© 2021 EUSA Pharma - Registered in England No. 9329429
Registered office: Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire, HP2 4TZ